X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DR. DATSONS LABS - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DR. DATSONS LABS IPCA LABS/
DR. DATSONS LABS
 
P/E (TTM) x 45.0 -10.9 - View Chart
P/BV x 3.5 0.2 2,126.9% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   DR. DATSONS LABS
EQUITY SHARE DATA
    IPCA LABS
Mar-17
DR. DATSONS LABS
Mar-14
IPCA LABS/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs643126 511.9%   
Low Rs50331 1,627.2%   
Sales per share (Unadj.) Rs254.4133.0 191.3%  
Earnings per share (Unadj.) Rs16.10.2 10,599.3%  
Cash flow per share (Unadj.) Rs29.86.6 450.6%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.6128.8 151.1%  
Shares outstanding (eoy) m126.2031.66 398.6%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x2.30.6 382.7%   
Avg P/E ratio x35.7516.1 6.9%  
P/CF ratio (eoy) x19.211.8 162.5%  
Price / Book Value ratio x2.90.6 484.7%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3002,477 2,918.4%   
No. of employees `00013.3NA-   
Total wages/salary Rs m6,96056 12,428.2%   
Avg. sales/employee Rs Th2,413.5NM-  
Avg. wages/employee Rs Th523.2NM-  
Avg. net profit/employee Rs Th152.4NM-  
INCOME DATA
Net Sales Rs m32,1064,211 762.5%  
Other income Rs m22679 286.8%   
Total revenues Rs m32,3324,289 753.8%   
Gross profit Rs m4,448569 782.2%  
Depreciation Rs m1,730204 846.1%   
Interest Rs m241430 56.0%   
Profit before tax Rs m2,70313 21,285.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6756 11,068.9%   
Profit after tax Rs m2,0285 42,250.0%  
Gross profit margin %13.913.5 102.6%  
Effective tax rate %25.048.0 52.0%   
Net profit margin %6.30.1 5,540.8%  
BALANCE SHEET DATA
Current assets Rs m17,3406,852 253.1%   
Current liabilities Rs m9,5596,711 142.5%   
Net working cap to sales %24.23.3 723.7%  
Current ratio x1.81.0 177.7%  
Inventory Days Days100161 62.4%  
Debtors Days Days57318 17.9%  
Net fixed assets Rs m20,7793,673 565.7%   
Share capital Rs m252317 79.7%   
"Free" reserves Rs m24,4993,761 651.4%   
Net worth Rs m24,5534,078 602.1%   
Long term debt Rs m3,5171,671 210.5%   
Total assets Rs m39,59512,633 313.4%  
Interest coverage x12.21.0 1,187.5%   
Debt to equity ratio x0.10.4 35.0%  
Sales to assets ratio x0.80.3 243.3%   
Return on assets %5.73.4 166.4%  
Return on equity %8.30.1 7,016.5%  
Return on capital %10.57.7 136.7%  
Exports to sales %48.622.9 212.5%   
Imports to sales %14.214.3 99.6%   
Exports (fob) Rs m15,617964 1,620.1%   
Imports (cif) Rs m4,571602 759.4%   
Fx inflow Rs m15,617964 1,620.1%   
Fx outflow Rs m5,828607 959.9%   
Net fx Rs m9,790357 2,743.0%   
CASH FLOW
From Operations Rs m2,7641,345 205.5%  
From Investments Rs m-1,432-2,256 63.5%  
From Financial Activity Rs m-1,591-1,200 132.6%  
Net Cashflow Rs m-259-2,111 12.3%  

Share Holding

Indian Promoters % 45.9 4.5 1,013.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.0 -  
FIIs % 25.3 1.4 1,874.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 94.1 18.5%  
Shareholders   36,892 20,807 177.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 23, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS